Quinoline

Quinoline

SCHEMBL2201840

NC(=O)O.c1ccc2ncccc2c1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.74
PABPC1 P11940 1/20 0.50
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 2/20 0.49
POLB P06746 2/20 0.49
MGAM O43451 2/20 0.48
PARP1 P09874 2/20 0.48
CASP1 P29466 2/20 0.48
HTT P42858 2/20 0.48
CASP7 P55210 1/20 0.48
TP53 P04637 1/20 0.48
HSP90AA1 P07900 1/20 0.48
HSP90AB1 P08238 1/20 0.48
TSHR P16473 1/20 0.48
ATM Q13315 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinoline SCHEMBL5272119 1.00 ALDH1A1 (0.74) ALDH1A1PABPC1KDM4EMEN1MAPT
Quinoline SCHEMBL1287895 0.96 ALDH1A1 (0.74) ALDH1A1PABPC1KDM4EMEN1MAPT
Quinoline SCHEMBL27782946 0.94 ALDH1A1 (0.71) ALDH1A1PABPC1KDM4EMEN1MAPT
Quinoline SCHEMBL5874493 0.93 ALDH1A1 (0.77) ALDH1A1PABPC1KDM4EMEN1MAPT
Quinoline SCHEMBL372690 0.93 ALDH1A1 (0.77) ALDH1A1PABPC1KDM4EMEN1MAPT
Quinoline SCHEMBL5283313 0.93 ALDH1A1 (0.77) ALDH1A1PABPC1KDM4EMEN1MAPT
Quinoline SCHEMBL28169251 0.92 ALDH1A1 (0.68) ALDH1A1PABPC1KDM4EMEN1MAPT
Quinoline SCHEMBL28197315 0.91 ALDH1A1 (0.74) ALDH1A1PABPC1KDM4EMEN1MAPT
Quinoline SCHEMBL5875384 0.91 ALDH1A1 (0.74) ALDH1A1PABPC1KDM4EMEN1MAPT
Quinoline SCHEMBL27473723 0.91 ALDH1A1 (0.74) ALDH1A1PABPC1KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1868998-B1 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS VFP THERAPIES (FR) 2016-05-25 EP disclosed
EP-2675790-B1 SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLIN-7-YL CARBAMATES AS ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE COUNCIL SCIENT IND RES (IN) 2015-11-18 EP disclosed
US-8946261-B2 Substituted 1, 2, 3, 4-tetrahydroquinolin-7-yl carbamates as acetylcholinesterase inhibitors for treatment of Alzheimer's disease COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-02-03 US disclosed
EP-2675790-A1 SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLIN-7-YL CARBAMATES AS ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE Council of Scientific & Industrial Research (IN) 2013-12-25 EP disclosed
US-20130324573-A1 SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLIN-7-YL CARBAMATES AS ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-12-05 US disclosed
WO-2012111021-A1 SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLIN-7-YL CARBAMATES AS ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860) (IN) 2012-08-23 WO disclosed
US-7977354-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents INSA ROUEN (FR) 2011-07-12 US disclosed
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2009-03-05 US disclosed
EP-1868998-A2 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS Insa Rouen (FR) 2007-12-26 EP disclosed
WO-2006103120-A2 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS NLN, SNCA, APP ALDH1A1 1663/4885PABPC1 4731/4885KDM4E 1927/4885
US-20130324573-A1 SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLIN-7-YL CARBAMATES AS ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE ACHE, BCHE, CHAT ALDH1A1 1202/4885PABPC1 4794/4885KDM4E 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.